AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17519792 — intervention group
Group type: COMPARATOR
Intervention: Control (CNI)
Number of subjects: 40
Study 16638294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential MV group (n = 47)
Number of subjects: 90
Study 16638294 — intervention group
Group type: COMPARATOR
Intervention: Conventional MV group (n = 43)
Number of subjects: 90
Study 14640819 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice
Number of subjects: 82
Study 14640819 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy generality
Number of subjects: 82
Study 14640819 — intervention group
Group type: COMPARATOR
Intervention: Constant practice
Number of subjects: 82
Study 10483953 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 85
Study 10483953 — intervention group
Group type: COMPARATOR
Intervention: PTCA alone (no further intervention)
Number of subjects: 85
Study 8954038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (1.0 microgram/kg)
Number of subjects: 0
Study 8954038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (0.5 microgram/kg)
Number of subjects: 0
Study 8954038 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH-(1-29)-NH2 (1.0 microgram/kg) + Hexarelin (0.125 microgram/kg)
Number of subjects: 0
Study 1673977 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 180 mg orally
Number of subjects: 0
Study 1673977 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) 0.5 mg nebulized aerosol
Number of subjects: 0
Study 1673977 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Terfenadine and Ipratropium bromide
Number of subjects: 0
Study 1673977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6460207 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (100, 200 or 300 mg, p.o.)
Number of subjects: 0
Study 6460207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6460207 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine and alcohol combination
Number of subjects: 0
Study 6460207 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine
Number of subjects: 0
Study 6460207 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 29192240 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 17
Study 26883950 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 International Units oxytocin once daily
Number of subjects: 32
Study 26883950 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 32
Study 25764160 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy with pegylated IFN‐α (subcutaneously weekly)
Number of subjects: 17
Study 23846820 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low‐dose spironolactone (50 mg/d) and metformin (1000 mg/d)
Number of subjects: 198
Study 23846820 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1000 mg/d)
Number of subjects: 198
Study 23846820 — intervention group
Group type: COMPARATOR
Intervention: Low‐dose spironolactone (50 mg/d)
Number of subjects: 198
Study 20618506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous siplizumab (0.012 mg/kg and 0.04 mg/kg every 2 weeks for 8 doses)
Number of subjects: 544
Study 20618506 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous siplizumab (5 mg x 12 weeks, 5 mg x 6 weeks + placebo x 6 weeks, 7 mg x 4 weeks + placebo x 8 weeks)
Number of subjects: 544
Study 20618506 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both I.V. and S.C. studies)
Number of subjects: 544
Study 18251761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg)
Number of subjects: 32
Study 18251761 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 microg (S100)
Number of subjects: 32
Study 18251761 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg (S50)
Number of subjects: 32
Study 18251761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 18251761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (Tio) vs Salmeterol 100 (S100)
Number of subjects: 32
Study 18251761 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol 100 (S100)
Number of subjects: 32
Study 18251761 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (Tio)
Number of subjects: 32
Study 15918199 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 48
Study 15918199 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 48
Study 12744899 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (PCV) conjugated to outer membrane protein of Neisseria meningitidis serogroup b, administered at 2, 4, 6, and 12 months of age.
Number of subjects: 49
Study 12744899 — intervention group
Group type: COMPARATOR
Intervention: Control group (32 infants not given PCV).
Number of subjects: 49
Study 12744899 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (PCV) after the 12 month dose.
Number of subjects: 49
Study 10567989 — intervention group
Group type: EXPERIMENTAL
Intervention: Endonasal shower (Siemens und Co, Bad Ems, Germany)
Number of subjects: 80
Study 10567989 — intervention group
Group type: COMPARATOR
Intervention: Sterilized solution (Rhinomer, Zyma SA, Nyon, France)
Number of subjects: 80
Study 9117049 — intervention group
Group type: EXPERIMENTAL
Intervention: Active antibiotic pastille
Number of subjects: 0
Study 9117049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1769828 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 0
Study 1769828 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study 7114439 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified adult circle system with Latexspiral tubing of 110 cm total length and internal diameter 10.5 mm, and a 'Y' piece with a small dead space.
Number of subjects: 0
Study 7114439 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified adult circle system with Latexspiral tubing
Number of subjects: 0
Study 7114439 — intervention group
Group type: COMPARATOR
Intervention: Kuhn- and Paedi-systems
Number of subjects: 0
Study 31867641 — intervention group
Group type: EXPERIMENTAL
Intervention: VLNC standard information
Number of subjects: 1712
Study 31867641 — intervention group
Group type: COMPARATOR
Intervention: No information about VLNC standard
Number of subjects: 1712
Study 28628684 — intervention group
Group type: EXPERIMENTAL
Intervention: Two treatment sessions using BodyFX bipolar RF device
Number of subjects: 8
Study 28628684 — intervention group
Group type: EXPERIMENTAL
Intervention: Three treatment sessions using BodyFX bipolar RF device
Number of subjects: 8
Study 28628684 — intervention group
Group type: COMPARATOR
Intervention: Eight weekly sessions using BodyFX bipolar RF device
Number of subjects: 8
Study 26116801 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 10^7 MSCs
Number of subjects: 21
Study 26116801 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 × 10^7 MSCs
Number of subjects: 21
Study 26116801 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 × 10^7 MSCs
Number of subjects: 21
Study 26116801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 24225174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 129
Study 24225174 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal training
Number of subjects: 129
Study 24225174 — intervention group
Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 129
Study 21474905 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 67
Study 19117319 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcal superantigen (SAg)‐specific IgE in adenoid tissue
Number of subjects: 40
Study 19117319 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcal superantigen (SAg)‐specific IgE in tonsil tissues
Number of subjects: 40
Study 19117319 — intervention group
Group type: EXPERIMENTAL
Intervention: Staphylococcal superantigen (SAg)‐specific IgE in serum
Number of subjects: 40
Study 19117319 — intervention group
Group type: EXPERIMENTAL
Intervention: High SEA levels
Number of subjects: 40
Study 19117319 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between SAg-specific IgE levels and tryptase levels
Number of subjects: 40
Study 18084976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency
Number of subjects: 0
Study 15526805 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg once daily)
Number of subjects: 122
Study 15526805 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg twice daily)
Number of subjects: 122
Study 15526805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 11247319 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. pamidronate (at 3-month intervals)
Number of subjects: 20
Study 11247319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 9439085 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg
Number of subjects: 613
Study 9439085 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 1 mg
Number of subjects: 613
Study 9439085 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 0.25 mg
Number of subjects: 613
Study 9439085 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 0.1 mg
Number of subjects: 613
Study 9439085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study 9439085 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of Naratriptan
Number of subjects: 613
Study 8502260 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic human growth hormone (Protropin)
Number of subjects: 75
Study 8502260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 3551212 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (8.5 ng/kg/min for an average of 64 hours)
Number of subjects: 80
Study 3551212 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle only)
Number of subjects: 80
Study 3551212 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 80
Study 3551212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 28901118 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training (MST) 3 times/week for 8 weeks
Number of subjects: 41
Study 28901118 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (SR) including physiotherapy sessions/telephone contact 1/week and writing home exercise logs
Number of subjects: 41
Study 27388361 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% chlorhexidine gluconate (CHG) in 70% alcohol
Number of subjects: 920
Study 27388361 — intervention group
Group type: COMPARATOR
Intervention: 0.5% chlorhexidine gluconate (CHG) in aqueous solution
Number of subjects: 920
Study 23873319 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 550 μg fluoride (F)/g, pH 4.5
Number of subjects: 48
Study 23873319 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: 1,100 μg F/g, pH 7.0
Number of subjects: 48
Study 23873319 — intervention group
Group type: COMPARATOR
Intervention: Group 3: 550 μg F/g, pH 7.0
Number of subjects: 48
Study 21610009 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-determined motivation
Number of subjects: 175
Study 21610009 — intervention group
Group type: COMPARATOR
Intervention: Non-progressors
Number of subjects: 175
Study 21610009 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular exercise at six months
Number of subjects: 175
Study 20103775 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 U of oral vitamin D2 at baseline and 10 weeks)
Number of subjects: 100
Study 20103775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 20103775 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 100
Study 18996875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-fortified salt with iron as micronized ground ferric pyrophosphate (MGFePP) at 2 mg/g salt
Number of subjects: 458
Study 18996875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-fortified salt with iron as encapsulated ferrous fumarate (EFF) at 2 mg/g salt
Number of subjects: 458
Study 18996875 — intervention group
Group type: COMPARATOR
Intervention: Iodized salt (IS)
Number of subjects: 458
Study 18996875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-fortified salt with iron as micronized ground ferric pyrophosphate (MGFePP)
Number of subjects: 458
Study 18996875 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-fortified salt with iron as encapsulated ferrous fumarate (EFF)
Number of subjects: 458
Study 16001284 — intervention group
Group type: EXPERIMENTAL
Intervention: T1-weighted MRI for whole-body adipose tissue quantification
Number of subjects: 150
Study 16001284 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume selective MRS for IHCL and IMCL determination
Number of subjects: 150
Study 16001284 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 150
Study 14586384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperstown cocktail
Number of subjects: 12
Study 14586384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperstown 5+1 cocktail
Number of subjects: 12
Study 11387359 — intervention group
Group type: EXPERIMENTAL
Intervention: epoetin alfa 150 to 300 IU/kg
Number of subjects: 375
Study 11387359 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 375
Study 9195022 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based rehabilitation (three visits per week for 6 weeks)
Number of subjects: 37
Study 9195022 — intervention group
Group type: COMPARATOR
Intervention: Home-based physical therapy (number of visits determined by patient response)
Number of subjects: 37
Study 1582794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmoscopy (indirect and direct) by a retina specialist
Number of subjects: 124
Study 1582794 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven standard field fundus photographs read by the same retina specialist
Number of subjects: 124
Study 1582794 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained photographic grader at the Fundus Photograph Reading Center
Number of subjects: 124
Study 1582794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmoscopy
Number of subjects: 124
Study 3011440 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg orally)
Number of subjects: 10
Study 31951599 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 polyunsaturated fatty acids (O-PUFA) for 8 weeks
Number of subjects: 73
Study 31951599 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control) for 8 weeks
Number of subjects: 73
Study 29742942 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose vaginal misoprostol
Number of subjects: 78
Study 29742942 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low dose vaginal misoprostol plus Foley catheter
Number of subjects: 78
Study 29240860 — intervention group
Group type: EXPERIMENTAL
Intervention: ixekizumab 80 mg injection every 2 weeks after a 160 mg starting dose
Number of subjects: 0
Study 29240860 — intervention group
Group type: EXPERIMENTAL
Intervention: etanercept 50 mg twice weekly
Number of subjects: 0
Study 29240860 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 26348584 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aripiprazole added to antidepressant therapy
Number of subjects: 225
Study 26348584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 26348584 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled response rates across phases and treatments
Number of subjects: 225
Study 23557594 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (2-16 mg/24 h)
Number of subjects: 287
Study 23557594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287
Study 21812544 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-on-child vignette
Number of subjects: 0
Study 21812544 — intervention group
Group type: COMPARATOR
Intervention: Adult-on-child vignette
Number of subjects: 0
Study 21812544 — intervention group
Group type: EXPERIMENTAL
Intervention: Male participants
Number of subjects: 0
Study 21812544 — intervention group
Group type: COMPARATOR
Intervention: Female participants
Number of subjects: 0
Study 18786961 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 30 microg adrenaline
Number of subjects: 270
Study 18786961 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (0.30 ml)
Number of subjects: 270
Study 16671841 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish Communication Screening at 18 months (SCS18)
Number of subjects: 2080
Study 16671841 — intervention group
Group type: COMPARATOR
Intervention: Traditional method of identification (informal assessment)
Number of subjects: 2080
Study 15638029 — intervention group
Group type: EXPERIMENTAL
Intervention: Aside-bending and up-standing method
Number of subjects: 261
Study 15638029 — intervention group
Group type: COMPARATOR
Intervention: Traditional massage method
Number of subjects: 261
Study 11159240 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg hyperbaric lidocaine 5% (n = 100)
Number of subjects: 200
Study 11159240 — intervention group
Group type: COMPARATOR
Intervention: 12 mg hyperbaric bupivacaine 0.75% (n = 100)
Number of subjects: 200
Study 9628552 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake 300 to 700 mg/d
Number of subjects: 430
Study 9628552 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake >700 mg/d
Number of subjects: 430
Study 9628552 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine intake >300 mg/d from coffee (smoking women)
Number of subjects: 430
Study 9628552 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking women with caffeine intake <300 mg/d
Number of subjects: 430
Study 9628552 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking women
Number of subjects: 430
Study 8143437 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer sealants (Fuji III)
Number of subjects: 166
Study 8143437 — intervention group
Group type: COMPARATOR
Intervention: Resin-based sealants (Delton)
Number of subjects: 166
Study 8143437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (glass-ionomer and resin-based)
Number of subjects: 166
Study 3060967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan 2 g administered during induction of anesthesia
Number of subjects: 71
Study 3060967 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis)
Number of subjects: 71
Study 2007795 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular TENS
Number of subjects: 3
Study 2007795 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no stimulation)
Number of subjects: 3
Study 1095262 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefruside
Number of subjects: 30
Study 1095262 — intervention group
Group type: COMPARATOR
Intervention: Cyclopenthiazide
Number of subjects: 30
Study 31306889 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong patient-surgeon relationship characterized by informational and emotional support
Number of subjects: 32
Study 31306889 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized disease- and treatment-related information
Number of subjects: 32
Study 31306889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate time for asking questions with thoughtful answers tailored to their case
Number of subjects: 32
Study 31306889 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional support from the surgeon characterized by empathy and validation
Number of subjects: 32
Study 31306889 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons acknowledging patients as unique individuals
Number of subjects: 32
Study 31306889 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal support from surgeons
Number of subjects: 32
Study 28835090 — intervention group
Group type: EXPERIMENTAL
Intervention: p16/Ki‐67 dual staining
Number of subjects: 980
Study 28835090 — intervention group
Group type: COMPARATOR
Intervention: Thinprep cytologic test (TCT)
Number of subjects: 980
Study 26003018 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal protection filter during PCI
Number of subjects: 85
Study 26003018 — intervention group
Group type: COMPARATOR
Intervention: No distal protection filter during PCI
Number of subjects: 85
Study 23929930 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (77 ± 9 mmol/d)
Number of subjects: 11
Study 23929930 — intervention group
Group type: COMPARATOR
Intervention: Normal-sodium diet (144 ± 7 mmol/d)
Number of subjects: 11
Study 21641348 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting technetium-99m tetrofosmin-gated single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
Number of subjects: 240
Study 21641348 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear variables added to clinical information
Number of subjects: 240
Study 21641348 — intervention group
Group type: EXPERIMENTAL
Intervention: LV phase SD
Number of subjects: 240
Study 19367181 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal enteral feeding (MEF) initiated 5 days after bowel reintegration, increased by 12 mL/kg/day
Number of subjects: 73
Study 19367181 — intervention group
Group type: COMPARATOR
Intervention: Control group with delayed enteral nutrition until resolution of postoperative ileus
Number of subjects: 73
Study 19367181 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal enteral feeding (MEF)
Number of subjects: 73
Study 19367181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional protocol
Number of subjects: 73
Study 16707406 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive control
Number of subjects: 0
Study 16707406 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual measurement
Number of subjects: 0
Study 16707406 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated measurement
Number of subjects: 0
Study 16707406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0